Cryo-Cell International, Inc.
General ticker "CCEL" information:
- Sector: Health Care
- Industry: Medical - Care Facilities
- Capitalization: $46.5M (TTM average)
Cryo-Cell International, Inc. does not follow the US Stock Market performance with the rate: -28.0%.
Estimated limits based on current volatility of 2.6%: low 3.33$, high 3.50$
Factors to consider:
- Company pays dividends (quarterly): last record date 2025-05-21, amount 0.15$ (Y17.44%)
- Total employees count: 86 (-2.3%) as of 2024
- Top business risk factors: Insufficient funding, Economic downturns and volatility, Regulatory and compliance, Political instability, ESG risks
- Current price 40.3% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-11-30 to 2026-11-30
- 2024-11-30 to 2025-11-30 estimated range: [5.99$, 9.86$]
- 2025-11-30 to 2026-11-30 estimated range: [5.76$, 9.69$]
Financial Metrics affecting the CCEL estimates:
- Positive: with PPE of 15.7 at the end of fiscal year the price was low
- Positive: 7.54 < Operating profit margin, % of 10.88
- Positive: 6.63 < Operating cash flow per share per price, % of 8.71
- Positive: -0.04 < Industry operating cash flow per share per price (median), % of 2.93
- Positive: -3.57 < Return on assets ratio (scaled to [-100,100]) of 0.62
- Negative: 0.74 < Interest expense per share per price, % of 2.70
- Negative: Shareholder equity ratio, % of -20.43 <= 19.35
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term CCEL quotes
Long-term CCEL plot with estimates
Financial data
| YTD | 2022-11-30 | 2023-11-30 | 2024-11-30 |
|---|---|---|---|
| Operating Revenue | $30.30MM | $31.34MM | $31.99MM |
| Operating Expenses | $26.27MM | $43.65MM | $28.51MM |
| Operating Income | $4.02MM | $-12.30MM | $3.48MM |
| Non-Operating Income | $-0.71MM | $-1.06MM | $-0.68MM |
| Interest Expense | $1.52MM | $1.24MM | $1.86MM |
| R&D Expense | $0.38MM | $1.17MM | $1.24MM |
| Income(Loss) | $3.32MM | $-13.36MM | $2.80MM |
| Taxes | $0.55MM | $-3.84MM | $2.40MM |
| Profit(Loss)* | $2.77MM | $-9.52MM | $0.40MM |
| Stockholders Equity | $-1.52MM | $-11.03MM | $-13.22MM |
| Inventory | $0.85MM | $0.77MM | $0.66MM |
| Assets | $64.89MM | $61.22MM | $64.68MM |
| Operating Cash Flow | $8.57MM | $8.92MM | $6.01MM |
| Capital expenditure | $17.17MM | $7.64MM | $2.40MM |
| Investing Cash Flow | $-15.28MM | $-8.14MM | $-4.88MM |
| Financing Cash Flow | $0.15MM | $-2.07MM | $-0.98MM |
| Earnings Per Share** | $0.33 | $-1.14 | $0.05 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.